Brief: HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab
05/06/2025 24:47
June 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ACCEPTED FOR REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text: ID:nHKS3DXz2 Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis